• INmune Bio agreed to sell 3,000,000 common shares in a registered direct offering for approximately $4.5 million in gross proceeds.
• A concurrent private placement includes unregistered warrants to purchase up to 3,000,000 common shares at an exercise price of $1.65.
• The warrants become exercisable six months following issuance and expire 5.5 years from issuance.
• The offering is expected to close around October 29, 2026, subject to customary closing conditions.
• Net proceeds will fund working capital and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280800PRIMZONEFULLFEED9854750) on October 28, 2026, and is solely responsible for the information contained therein.